![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 100 Results From the SWORD-1 and SWORD-2 Studies
|
|
|
Reported by Jules Levin
Glasgow 2018 Oct 27-31
Alan Oglesby,1Kostas Angelis,2Yogesh Punekar,3Sara Lopes,3Antonio Antela,4Michael Aboud,3Rodicavan Solingen,5Elizabeth Blair,1Lesley Kahl,3Martin Gartland,1Brian Wynne,1Miranda Murray3
1ViiV Healthcare, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Uxbridge, UK; 3ViiV Healthcare, Brentford, UK; 4Infectious Diseases Unit, Hospital Clinico de Santiago, La Coruna, Spain; 5Janssen PharmaceuticaNV, Beerse, Belgium
![1105181](../images%20/110518/110518-7/1105181.gif)
![1105182](../images%20/110518/110518-7/1105182.gif)
![1105183](../images%20/110518/110518-7/1105183.gif)
![1105184](../images%20/110518/110518-7/1105184.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|